Marfan Syndrome

Marfan syndrome is an autosomal dominant disorder of connective tissue caused by pathogenic variants in the FBN1 gene on chromosome 15, which encodes fibrillin-1 — a glycoprotein essential for the structural integrity of elastic fibers in the extracellular matrix. Loss of functional fibrillin-1 disrupts microfibril scaffolding and, critically, releases latent TGF-β from its matrix reservoir, causing excess TGF-β signaling that drives the cardiovascular, skeletal, and ocular manifestations of the disease. The syndrome affects approximately 1 in 5,000 people worldwide and carries life-threatening cardiovascular risk — primarily progressive aortic root dilation leading to dissection — that requires lifelong monitoring and prophylactic intervention.

Overview and Genetics
Pathophysiology
Skeletal Features
Cardiovascular Manifestations
Ocular Manifestations
Ghent Nosology and Diagnosis
Differential Diagnosis and MASS Phenotype
Medical and Surgical Management
Surveillance and Monitoring
Prognosis and Life Expectancy
Recent Research
References

1. Overview and Genetics

Marfan syndrome was first described by the French pediatrician Antoine Marfan in 1896, who reported a five-year-old girl with disproportionately long limbs and digits. The molecular basis was established in 1991 when Dietz and colleagues identified mutations in FBN1 on chromosome 15q21.1 as the causative defect. The condition follows autosomal dominant inheritance with virtually complete penetrance, though expressivity is highly variable — even within the same family, individuals carrying identical mutations may range from severely affected to mildly symptomatic.

Approximately 25–30% of cases arise from de novo mutations (no affected parent). FBN1 is among the largest human genes (110 kb, 65 exons) and over 3,000 distinct pathogenic variants have been catalogued, the majority being missense mutations that substitute a cysteine residue in one of the calcium-binding epidermal growth factor (cbEGF)-like domains of fibrillin-1, disrupting protein folding and secretion. The prevalence is approximately 1 in 5,000 to 1 in 10,000 births with no sex or ethnic predilection.

2. Pathophysiology

Fibrillin-1 and Microfibril Structure

Fibrillin-1 is a large (350 kDa) cysteine-rich glycoprotein that polymerizes head-to-tail into microfibrils — 10–12 nm diameter structures that serve as the architectural scaffold for elastin deposition and as load-bearing cables in connective tissues that lack elastin (zonular fibers of the lens, periosteum, dura mater). In the aorta and large vessels, fibrillin-1 microfibrils anchor smooth muscle cells to the elastic lamellae and provide the template around which elastin matures. Loss of intact fibrillin-1 weakens the arterial wall mechanically and renders the extracellular matrix incapable of sequestering the latent TGF-β complex.

TGF-β Dysregulation

The dominant pathomechanism in Marfan syndrome is excess TGF-β signaling, not simply structural fibrillin-1 deficiency. Fibrillin-1 normally binds the large latent TGF-β complex (LLC), holding it inactive in the matrix. When fibrillin-1 is deficient or mutant, LLC is inadequately sequestered, and bioavailable TGF-β (isoforms 1, 2, and 3) rises dramatically. Excess TGF-β activates SMAD2/3 and non-SMAD (ERK, p38 MAPK) pathways, promoting:

Aortic smooth muscle cell apoptosis and loss of vascular smooth muscle differentiation markers
Elastic fiber fragmentation (elastolysis) in the aortic media
Airspace enlargement in the lung (contributing to spontaneous pneumothorax)
Overgrowth of long bones (skeletal manifestations)

This TGF-β excess hypothesis, validated in Fbn1^C1039G/+ mouse models by Loeys, Dietz, and colleagues, explains why angiotensin II receptor blockers (ARBs) — which reduce TGF-β signaling — show benefit beyond their hemodynamic effects alone.

Haploinsufficiency vs. Dominant Negative

Some mutations cause haploinsufficiency (reduced total fibrillin-1 output), while cysteine-substitution missense mutations act through a dominant-negative mechanism — the mutant protein is secreted but interferes with wild-type fibrillin-1 polymerization, amplifying structural disruption beyond what simple 50% reduction would predict. This mechanistic distinction partially explains the variable severity observed across different mutation classes.

3. Skeletal Features

Skeletal manifestations reflect the overgrowth of long bones driven by excess TGF-β signaling in the periosteum and growth plate. The characteristic findings collectively constitute the "marfanoid habitus."

Proportional Measurements

Tall stature: Most patients are above the 95th percentile for height; disproportionate lower-limb elongation is typical
Arm span exceeds height: Arm span-to-height ratio >1.05 (normal ≤1.03); measured fingertip-to-fingertip; reflects selective elongation of the upper extremities
Reduced upper-to-lower segment (US:LS) ratio: The US (crown to pubic symphysis) divided by LS (pubic symphysis to floor) is <0.85 in adults with Marfan syndrome (normal ~1.0 in adults); reflects disproportionately long legs

Specific Skeletal Signs

Arachnodactyly (spider fingers): Abnormally long, slender digits; assessed by two clinical tests:
- Wrist sign (Walker-Murdoch): Positive when thumb and fifth finger overlap when wrapped around the contralateral wrist — 1 point in systemic scoring
- Thumb sign (Steinberg): Positive when thumb, placed across the palm, protrudes beyond the ulnar border — 1 point (combined wrist + thumb = 3 points)
Pectus deformity: Pectus excavatum (funnel chest, requires surgery or bracing) scores 2 points; pectus carinatum (pigeon chest) scores 2 points; pectus excavatum or chest asymmetry scores 1 point
Scoliosis: Occurs in 40–70% of patients; thoracic curves most common; Cobb angle ≥20° scores 1 point in systemic scoring
Hindfoot deformity: Pes planus (flatfoot) with valgus hindfoot alignment — 2 points in systemic scoring
High-arched palate: Narrow, highly vaulted palate with dental crowding due to craniofacial undergrowth — part of facial feature scoring
Reduced elbow extension: Maximum elbow extension <170° — 1 point in systemic scoring
Protrusio acetabuli: Protrusion of the femoral head medially into the pelvis on plain radiograph — 2 points; may cause hip pain and early arthritis
Facial features: Dolichocephaly (elongated skull), enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia — scoring up to 1 point total for ≥3 features

4. Cardiovascular Manifestations

Cardiovascular involvement is the primary determinant of prognosis and the leading cause of death in Marfan syndrome. Before the era of prophylactic aortic root replacement, median life expectancy was approximately 32 years. With modern surgical and medical management, life expectancy approaches that of the general population.

Aortic Root Dilation and Dissection

Dilation of the aortic root (sinuses of Valsalva) is the cardinal cardiovascular feature, present in 60–80% of adults with Marfan syndrome. The pathological process — elastic fiber fragmentation, smooth muscle cell loss, "cystic medial necrosis" (a misnomer, as the changes are not truly cystic) — begins in utero and progresses throughout life. Key thresholds:

Z-score ≥2: Defines aortic root dilation in the 2010 Ghent nosology (corrected for age and body surface area using the formula of Roman or Devereux)
4.5–5.0 cm absolute diameter: Threshold for prophylactic aortic root replacement in most guidelines
>5 mm/year growth rate: Rapid progression requiring expedited surgery regardless of absolute diameter

Type A aortic dissection (ascending aorta, DeBakey I/II) is the catastrophic complication, carrying 1–2% per hour mortality if untreated. Dissection risk increases exponentially above 5.0 cm. Dissections in Marfan syndrome can occur at smaller diameters than in non-connective-tissue-disorder patients, and may occur during pregnancy (particularly third trimester and peripartum) due to hemodynamic and hormonal changes.

Mitral Valve Prolapse

Mitral valve prolapse (MVP) occurs in 50–80% of Marfan patients, often with myxomatous degeneration of the leaflets (redundant, billowing leaflets with elongated chordae). Most cases are hemodynamically insignificant, but 5–10% develop significant mitral regurgitation requiring repair or replacement. MVP in Marfan syndrome tends to be more severe than isolated MVP in the general population and may cause arrhythmias (ventricular ectopy) and, rarely, sudden cardiac death.

Other Cardiovascular Features

Tricuspid valve prolapse: Less common than MVP; usually incidental
Pulmonary artery dilation: At the bifurcation; rarely causes clinical problems
Descending thoracic and abdominal aortic dilation: Can occur after successful aortic root replacement; requires ongoing surveillance
Aortic regurgitation: Secondary to aortic root dilation stretching the aortic annulus; may be the presenting cardiac symptom

5. Ocular Manifestations

Ectopia Lentis

Ectopia lentis (lens subluxation or dislocation) is the pathognomonic ocular sign of Marfan syndrome, occurring in 50–80% of patients. The zonular fibers (suspensory ligaments of the lens) are composed almost entirely of fibrillin-1 microfibrils; their structural failure allows the lens to sublux from its normal position. In Marfan syndrome, subluxation is characteristically bilateral and superotemporal (upward and outward).

This directionality is a critical diagnostic differentiator: in homocystinuria (the main metabolic mimic of Marfan syndrome), ectopia lentis is inferonasal (downward and inward), reflecting the different pathomechanism (disruption of zonular sulfide cross-links by elevated homocysteine rather than fibrillin-1 structural failure). Slit-lamp examination is required for detection; patients may report monocular diplopia or progressive myopia.

Other Ocular Findings

Myopia: Axial myopia (elongated globe) is near-universal; average refractive error −3 to −5 diopters; associated with increased risk of retinal detachment
Increased axial length: The globe is elongated; measures typically >25 mm (normal ~24 mm)
Flat cornea (cornea plana): Reduced corneal curvature; lower intraocular pressure due to increased facility of aqueous outflow
Early-onset cataracts: Nuclear sclerosis in the third and fourth decade
Glaucoma: Open-angle glaucoma at elevated risk, partly from microspherophakia and secondary angle-closure
Retinal detachment: Significantly elevated risk (8×) compared to general population; related to high myopia and peripheral retinal lattice degeneration; requires prompt ophthalmologic evaluation of any new floaters or visual field changes

6. Ghent Nosology and Diagnosis

The revised Ghent nosology (2010), published by Loeys et al. in the Journal of Medical Genetics, replaced the original 1996 Ghent criteria and provides the current diagnostic framework. It incorporates molecular data (FBN1 mutation status) and aortic Z-scores, and de-emphasizes non-specific minor criteria that led to over-diagnosis.

Diagnostic Scenarios

In the absence of a family history of Marfan syndrome, diagnosis requires one of four scenarios:

Aortic root Z-score ≥2 AND ectopia lentis = Marfan syndrome
Aortic root Z-score ≥2 AND FBN1 causative variant = Marfan syndrome
Aortic root Z-score ≥2 AND systemic score ≥7 = Marfan syndrome
Ectopia lentis AND FBN1 variant known to be associated with aortic disease = Marfan syndrome

With a family history of confirmed Marfan syndrome (per the above criteria), the threshold is lower: ectopia lentis alone, systemic score ≥7 alone, or aortic Z-score ≥2 alone each suffice.

Systemic Score Components

Feature	Points
Wrist AND thumb sign	3
Wrist OR thumb sign (not both)	1
Pectus carinatum deformity	2
Hindfoot deformity	2
Spontaneous pneumothorax	2
Dural ectasia on MRI	2
Protrusio acetabuli	2
Reduced US/LS ratio AND increased arm span/height, no severe scoliosis	1
Scoliosis or thoracolumbar kyphosis	1
Reduced elbow extension (<170°)	1
Facial features (3 of 5: dolichocephaly, enophthalmos, downslanting fissures, malar hypoplasia, retrognathia)	1
Skin striae	1
Myopia >3 diopters	1
MVP by echocardiography	1
Pectus excavatum or chest asymmetry	1

Maximum systemic score is 20; a score ≥7 is clinically significant. No single feature is pathognomonic in isolation; the systemic score captures the cumulative connective tissue burden.

Aortic Z-Score Calculation

The aortic root diameter measured at end-diastole at the level of the sinuses of Valsalva on transthoracic echocardiography is converted to a Z-score using age- and body surface area-corrected normative data. A Z-score of 2 corresponds to 2 standard deviations above the mean for a given age and BSA. Online calculators using the equations of Roman et al. or Devereux et al. are widely used; the 2010 Ghent criteria specify using these reference equations explicitly.

7. Differential Diagnosis and MASS Phenotype

The Ghent nosology was designed partly to prevent over-diagnosis of Marfan syndrome in patients with overlapping connective tissue features. Several conditions require distinction:

MASS Phenotype

MASS (Mitral valve prolapse, Aortic root dilation below Z-score 2, Skin striae, Skeletal features) is a phenotypically overlapping condition that does not meet Ghent criteria for Marfan syndrome. Some MASS patients harbor heterozygous FBN1 variants of uncertain significance. MASS does not carry the same cardiovascular risk as Marfan syndrome, though aortic surveillance remains prudent.

Key Differential Diagnoses

Loeys-Dietz syndrome (LDS): TGFBR1 or TGFBR2 mutations; clinically overlaps with Marfan but characterized by bifid uvula, hypertelorism, and arterial tortuosity; aortic dissection at smaller diameters — surgical threshold lower (4.0–4.5 cm); distinguished by genetic testing
Homocystinuria: CBS gene mutation, autosomal recessive; marfanoid habitus + ectopia lentis (inferonasal, not superotemporal) + intellectual disability + thromboembolic events; elevated plasma homocysteine; responds to pyridoxine supplementation
Ehlers-Danlos syndrome (vascular type, EDS-IV): COL3A1 mutations; skin hyperextensibility, joint hypermobility, thin translucent skin, arterial/intestinal/uterine rupture; ectopia lentis absent; diagnosis by molecular testing
Congenital contractural arachnodactyly (Beals syndrome): FBN2 mutations; joint contractures (not laxity), crumpled ear pinna; minimal cardiovascular involvement; distinguished by FBN2 gene testing
ACROMEGALY: Pituitary GH excess; tall stature, enlarged hands and feet, but coarse facial features, prognathism, and elevated IGF-1 distinguish it
Constitutional tall stature: Normal proportions, no systemic connective tissue features
Familial thoracic aortic aneurysm/dissection (FTAAD): ACTA2, MYH11, SMAD3, MYLK, PRKG1 mutations; isolated aortic disease without skeletal/ocular features

8. Medical and Surgical Management

Beta-Blockers

Beta-adrenergic blockade has been the cornerstone of medical management since the landmark 1994 NEJM trial by Shores et al., which demonstrated that atenolol significantly reduced the rate of aortic dilation, the onset of aortic regurgitation, and clinical endpoints (death, cardiovascular surgery, aortic regurgitation, dissection) compared to placebo in a randomized trial of 70 patients followed for 10 years. The mechanism involves reduction in dP/dt (rate of pressure rise), decreasing mechanical stress on the aortic wall with each cardiac cycle.

Atenolol: 1–2 mg/kg/day; most commonly used agent; once-daily dosing aids adherence; target resting heart rate 60–70 bpm
Propranolol: Historically used; non-selective; 2–4 mg/kg/day in divided doses; still used in pediatric patients
Beta-blockers are recommended for all patients with Marfan syndrome who can tolerate them, regardless of aortic diameter

Angiotensin II Receptor Blockers (ARBs)

The rationale for ARBs in Marfan syndrome is compelling: losartan antagonizes AT1 receptors and, independently of its blood pressure-lowering effect, reduces TGF-β signaling in the aortic wall — the key pathomechanism. In the Fbn1^C1039G/+ mouse model, losartan abolished aortic root dilation and normalized TGF-β signaling at doses that did not affect blood pressure.

The COMPARE trial (Randomized Comparison of Losartan Versus Atenolol in Marfan Syndrome, published in Lancet 2013) was the pivotal head-to-head clinical trial randomizing 233 Marfan patients to losartan or atenolol for 3 years. Both arms showed significant reduction in aortic root growth rate, with no statistically significant difference between them. Subsequent trials (including the PEDIATRIC MARFAN trial and the UK-based AIMS trial) confirmed that losartan is at least as effective as beta-blockade and may offer additive benefit when combined. Current guideline consensus:

ARBs (losartan or irbesartan) are appropriate first-line therapy, alone or combined with beta-blockers
Combination therapy (beta-blocker + ARB) is increasingly used in patients with rapid progression or large aortic dimensions
ACE inhibitors are generally avoided (may up-regulate TGF-β via Ang II-independent pathways)

Prophylactic Aortic Root Replacement

Elective surgical replacement of the aortic root eliminates the risk of dissection from the most vulnerable aortic segment. The major techniques include:

Bentall procedure: Composite graft replacement of the aortic root and ascending aorta with a mechanical valve prosthesis sewn in; durable but requires lifelong anticoagulation
Valve-sparing aortic root replacement (VSARR): David (reimplantation) or Yacoub (remodeling) techniques preserve the native aortic valve, eliminating anticoagulation; favored in younger patients and in experienced centers; excellent long-term outcomes (freedom from reoperation >90% at 10 years in the Gott series)

Indications for elective surgery (per AHA/ACC and ESC guidelines):

Aortic root diameter ≥5.0 cm (Class I recommendation)
Aortic root diameter ≥4.5 cm in patients planning pregnancy, with rapid growth (>5 mm/year), with significant aortic regurgitation, or with a family history of dissection at small diameters (Class IIa)
Rapid growth rate >5 mm/year at any diameter (Class I)

Additional Management Considerations

Activity restriction: Competitive contact sports, isometric exercise, and activities involving rapid acceleration/deceleration are contraindicated; low-to-moderate aerobic exercise (swimming, walking, cycling) is encouraged
Pregnancy: High-risk; aortic root should be <4.0 cm before conception; monthly echocardiographic surveillance during pregnancy; delivery by elective caesarean section if root >4.0 cm or rapidly growing; beta-blockers continued (atenolol avoided due to fetal growth restriction — metoprolol preferred)
Ophthalmologic: Corrective lenses; surgical lensectomy for significant ectopia lentis; cataract extraction when indicated; annual retinal screening for detachment risk
Orthopedic: Physical therapy for scoliosis; bracing for mild-moderate curves; posterior spinal fusion for progressive curves >45–50°; pectus repair for symptomatic deformity
Dural ectasia: Often asymptomatic; symptomatic cases (low back pain, leg pain, headache) may require epidural blood patch or, rarely, surgical repair

9. Surveillance and Monitoring

Lifelong, structured surveillance is essential given the progressive nature of aortic disease. Recommended surveillance schedule:

Echocardiography: At diagnosis; if stable, annually; if aortic root approaches 4.5 cm or is growing, every 6 months; MRI/CT angiography for full aortic imaging (root to iliac) at initial evaluation and every 3–5 years thereafter, or sooner if echocardiographic windows are poor
Ophthalmology: Annual slit-lamp examination for ectopia lentis; annual dilated fundus examination for retinal detachment; intraocular pressure monitoring
Genetics: Molecular testing (FBN1 sequencing + deletion/duplication analysis) recommended for all patients and first-degree relatives; genetic counseling for reproductive planning
Orthopedics/Physical therapy: Annual scoliosis assessment (clinical and radiographic if progressing); assessment of pectus and joint laxity
Pediatric surveillance: Children and adolescents often require more frequent imaging (every 6 months) during rapid growth phases

10. Prognosis and Life Expectancy

The natural history of Marfan syndrome has been transformed by modern cardiovascular management. Before the 1970s — prior to systematic echocardiographic surveillance, beta-blocker therapy, and prophylactic aortic surgery — median survival was approximately 32 years, with most deaths from aortic dissection or heart failure. By the 1990s, survival had improved to ~72 years. Contemporary cohort data suggest that patients followed in specialist centers now have life expectancy approaching that of the general population, provided aortic disease is identified early and managed prophylactically.

Key prognostic factors include: initial aortic root diameter at diagnosis, rate of dilation, adherence to medical therapy, and availability of experienced surgical care. Women generally have better cardiovascular outcomes than men, though pregnancy carries significant risk. Patients who have undergone successful prophylactic aortic root replacement still require surveillance of the remainder of the aorta, as descending thoracic and abdominal aneurysms can develop over decades.

11. Recent Research

Combination losartan + atenolol: Several RCTs and meta-analyses have evaluated whether adding an ARB to beta-blockade provides incremental benefit over either agent alone. The 2019 PEDIATRIC MARFAN study and the UK AIMS trial support combination therapy in high-risk patients (rapid dilation, large root); ongoing work continues to define optimal patient selection
TGF-β isoform specificity: Research distinguishing TGF-β1 from TGF-β2 and TGF-β3 signaling identifies TGF-β2 as disproportionately elevated in Marfan aorta and a potential selective therapeutic target
Periodontal/microbiome links: Emerging data suggest gut microbiome alterations in Marfan syndrome, with potential inflammatory contributions to aortic wall remodeling beyond TGF-β
iPSC-derived smooth muscle cells: Patient-derived induced pluripotent stem cell models of Marfan aortic smooth muscle cells now allow drug testing in vitro, accelerating candidate identification
Modified Z-score calculators: Refined BSA-corrected nomograms, particularly for children and patients with extreme body habitus, are being validated to improve diagnostic precision of the aortic Z-score criterion
Doxycycline: As an MMP inhibitor, doxycycline has been shown to reduce aortic dilation in Marfan mouse models; small human pilot trials are ongoing
Featured Videos

12. References

Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–339. PMID: 1852208
Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics. 2010;47(7):476–485. PMID: 20591885
Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. New England Journal of Medicine. 1994;330(19):1335–1341. PMID: 8152445
Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. New England Journal of Medicine. 1999;340(17):1307–1313. PMID: 10219065
Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial (COMPARE). European Heart Journal. 2013;34(45):3491–3500. PMID: 23999449
Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nature Genetics. 2003;33(3):407–411. PMID: 12598898
Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome (PEDIATRIC HEART NETWORK MARFAN TRIAL). New England Journal of Medicine. 2014;371(22):2061–2071. PMID: 25405392
Dietz HC, Cutting GR, Pyeritz RE. Marfan syndrome. New England Journal of Medicine. 1994;330(19):1366–1368. PMID: 8152456
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. New England Journal of Medicine. 2008;358(26):2787–2795. PMID: 18579813
Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. American Journal of Human Genetics. 2007;81(3):454–466. PMID: 17701892
Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. American Journal of Cardiology. 1989;64(8):507–512. PMID: 2773795
Jondeau G, Detaint D, Tubach F, et al. Aortic event rate in the Marfan population: a cohort study. Circulation. 2012;125(2):226–232. PMID: 22128340

Back to Table of Contents

Research Papers

Explore current literature on Marfan syndrome via PubMed topic searches. These links open live PubMed searches for the listed keywords — results update as new studies are indexed.

↑ Back to Table of Contents

Connections